Fund Holdings — Fairmount Funds Management LLC

Total Portfolio Value:
$771.90M
Total Bought:
$123.21M
Total Sold:
$10.22M
Net Transaction:
+$112.99M
Notable People:
Tomas Kiselak, Peter Evan Harwin
Securities
▲▼
SharesValue
Q1 2025
▲▼
Q2 2025
▲▼
Change
▲▼
Q1 2025
▲▼
Q2 2025
▲▼
Weight (%)
▲▼
Change
▲▼
Apogee Therapeutics Inc2,048,6472,048,6470$76.54M$88.97M11.53%+$12.44M
Axsome Therapeutics, Inc.(AXSM)815,176815,1760$95.07M$85.10M11.02%-$9.98M
Enliven Therapeutics Inc3,202,7983,711,444+508,646$63.03M$74.45M9.65%+$11.42M
Scholar Rock Holding Corporation(SRRK)1,374,0311,824,031+450,000$44.18M$64.61M8.37%+$20.43M
Spyre Therapeutics, Inc.(SYRE)4,018,1014,018,1010$64.83M$60.15M7.79%-$4.68M
Nuvalent Inc727,563727,5630$51.60M$55.51M7.19%+$3.91M
Dianthus Therapeutics, Inc.(DNTH)2,700,6912,707,191+6,500$48.99M$50.43M6.53%+$1.44M
Kiniksa Pharmaceuticals International, plcCL A(KNSA)1,102,2481,772,839+670,591$24.48M$49.05M6.36%+$24.57M
Viridian Therapeutics, Inc.(VRDN)3,445,8133,459,913+14,100$46.45M$48.37M6.27%+$1.92M
Cogent Biosciences, Inc.(COGT)6,225,6416,225,6410$37.29M$44.70M5.79%+$7.41M
Oruka Therapeutics, Inc.(ORKA)3,371,9223,371,9220$34.60M$37.80M4.90%+$3.20M
Jade Biosciences Inc03,220,368+3,220,368$0$32.17M4.17%+$32.17M
Crescent Biopharma, Inc.(CBIO)01,387,866+1,387,866$0$22.40M2.90%+$22.40M
Astria Therapeutics Inc3,554,1293,554,1290$18.98M$19.05M2.47%+$71.1K
Zenas BioPharma, Inc.(ZBIO)1,892,8061,892,8060$14.95M$18.34M2.38%+$3.39M
Inhibikase Therapeutics, Inc.(IKT)6,125,0006,125,0000$13.41M$11.94M1.55%-$1.47M
CytomX Therapeutics, Inc.(CTMX)03,896,582+3,896,582$0$8.85M1.15%+$8.85M
Bicara Therapeutics Inc784,1700-784,170$10.22M$0—-$10.22M
Page 1 of 1
Fairmount Funds Management LLC — 13F Holdings — Q2 2025 | TickerTrail